Diabetes patients could be offered weight loss jabs sooner in major shake-up
Millions of diabetes patients could receive weight loss jabs sooner
- New draft guidance from Nice proposes a significant overhaul of type 2 diabetes care in England, moving towards personalised treatment to prevent serious complications.
- SGLT-2 inhibitors, which protect the heart and kidneys, are recommended as a first-line treatment option, potentially saving nearly 22,000 lives.
- The guidelines aim to address the current under-prescription of SGLT-2 inhibitors, particularly among women, older people, and black patients, to reduce health inequalities.
- GLP-1 receptor agonists, including semaglutide, are also suggested for earlier use in some patients, alongside tailored recommendations for specific conditions.
- This shift represents a holistic approach to type 2 diabetes management, focusing on cardiovascular and kidney health, and is open for public consultation until 2 October.